European best practice guidelines for peritoneal dialysis. 1 General guidelines.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Mariano Feriani.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: A large percentage of peritoneal dialysis (PD) patients being treated with standard lactate-containing solutions tend to have serum bicarbonate concentrations below or above the normal range. The inter-patient variability of serum bicarbonate is a result of many influences and it may be appropriate to adjust the bicarbonate concentration in the peritoneal dialysis fluid (PDF) to the current serum bicarbonate in the individual patient. METHODS: Two concentrations of bicarbonate in PDF were compared in this study (34 and 39 mmol/l). Eligible patients underwent a pre-study phase of 12 weeks to determine serum bicarbonate every six weeks. Sixty-one patients entered the stratification phase. Acidotic patients (serum venous bicarbonate <25.3 mmol/l) were allocated to the high bicarbonate solution, patients in the normal serum bicarbonate range or alkalotic patients (serum venous bicarbonate >25.3 mmol/l) to the low bicarbonate solution. Patients were followed up for 24 weeks, in which study visits were performed every 6 weeks to assess acid-base status, peritoneal and renal function, and to calculate protein nitrogen appearance rate (PNA). RESULTS: Patients with acidosis at baseline had higher body weight, body surface area, blood urea nitrogen, serum creatinine and PNA than patients with bicarbonate within the normal range or with alkalosis. They significantly improved their serum bicarbonate (23.45 +/- 2.5 vs 25.7 +/- 2.8 mmol/l, baseline vs week 24; P < 0.01), whereas patients treated with the low bicarbonate PDF maintained their serum venous bicarbonate over the 24 week study period (27.77 +/- 2.9 vs 27.06 +/- 2.1 mmol/l, baseline vs week 24; P = NS). Analysing both study groups together, at baseline, 66% of the patients presented with mild to moderate acidosis, this figure at the end of the study was 23.4%. PNA did not change in the two groups; however, in the subgroup of patients (N = 23) in whom the 39 mmol/l PDF was effective in correcting metabolic acidosis, a decrease in PNA was observed. CONCLUSIONS: The study demonstrated that the individualized application of low and high bicarbonate PD PDFs allows one to achieve normal acid-base status in a large percentage of CAPD patients with potential benefits to nutritional status.
The feedback between metabolic acid production and dialytic base gain ensures a neutral acid-base balance in patients on renal replacement therapy (RRT). Despite acid not accumulating continuously, clinical studies demonstrated that normalizing pre-dialysis serum bicarbonate results in nutritional and osteodystrophy improvements. Full correction of acidosis is not an easy task in dialysis patients because it depends on both some intrinsic characteristics of patients and dialysis prescriptions. Thus, a large variation in the result is often recorded among dialysis populations and in acid-base studies. Highly convective dialysis treatments make the individualization of dialytic parameters easier than conventional dialysis. Up to now, few clinical data have been published. However, knowledge of and the quantification of the kinetic phenomena that govern the buffer transfer during a session of these high performance treatments can provide a rational approach to the optimal dialysis prescription.
The concept of dialysis adequacy has to be widened to include medium size and large molecule removal in addition to urea kinetics. The HEMO study found a non-significant trend toward a beneficial effect on mortality of high-flux dialysis compared with low-flux dialysis. In that study, the beneficial effect of convection could have been attenuated by the fact that 'internal filtration' in high-flux haemodialysis (HD) is lower than that expected by convection in haemofiltration (HF) or haemodiafiltration (HDF). To explore the putative beneficial effect of convection, this Italian multicentre study was planned, comparing on-line convective treatments (HF and HDF) with standard, low-flux HD. The enrolled patients will be evaluated prospectively on their usual treatment for 2 months (baseline period) and subsequently randomized to continue either with low-flux HD (50%) or to start on-line convective treatment (50%), HF or HDF according to a 1:1 ratio. The primary end point of the study will be cardiovascular stability and blood pressure control. As secondary aims of the study, the impact on symptoms, morbidity and mortality will be assessed. Feasibility and patient compliance during HF and HDF treatments will also be evaluated. The experimental phase of the study, of at least 2 years, is divided into a 3-month adaptation period and a subsequent evaluation period. A recruitment period of 1 year is planned. The study design has adequate power to detect an absolute reduction of 3% hypotensive episodes with the experimental convective treatments compared with standard low-flux HD.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.